BioAge Labs
United States
About BioAge Labs
19 articles about BioAge Labs
-
BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors
4/9/2024
BioAge Labs, Inc. today announced the appointment of Michael Davidson, MD to the company's board of directors.
-
BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics
2/13/2024
BioAge Labs (“BioAge”), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, announced today the completion of an oversubscribed Series D financing round of $170 million led by Sofinnova Investments.
-
The startup will use the money to fund a Phase II trial in combination with Eli Lilly’s Zepbound in the hopes of increased weight loss results, while attempting to protect body composition from muscle wasting.
-
BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization
10/26/2023
BioAge Labs, Inc., (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced plans to initiate a Phase 2 trial of its oral apelin receptor agonist BGE-105 (azelaprag) co-administered with the GLP-1/GIP receptor agonist tirzepatide for treatment of obesity.
-
BioAge Labs Appoints BJ Sullivan as Chief Strategy Officer
5/22/2023
BioAge Labs, Inc., a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, announced the appointment of BJ Sullivan, Ph.D., as Chief Strategy Officer.
-
BioAge Labs to Present on Therapeutics for Brain Aging Targeting NLRP3, Apelin, and Other Novel Pathways at Upcoming International Conferences
4/26/2023
BioAge Labs, Inc. (“BioAge”) today announced that the company will provide updates on the company's progress in novel target identification and drug development in the brain aging area at upcoming conferences in the US and UK.
-
BioAge Hosting Webcast to Discuss Newly Announced Phase 1b Data Demonstrating BGE-105 Significantly Improves Muscle Atrophy in Older Volunteers on Bed Rest and Detail Phase 2 Plans
12/14/2022
BioAge Labs, Inc. (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that the company will host an online key opinion leader (KOL) event for analysts, investors, and other interested parties on its first-in-class apelin receptor agonist BGE-105.
-
BioAge Announces Positive Topline Results for BGE-105 in Phase 1b Clinical Trial Evaluating Muscle Atrophy in Older Volunteers at Bed Rest
12/5/2022
BioAge Labs, Inc. (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced positive Phase 1b clinical data for BGE-105, a highly selective, potent, orally available small-molecule agonist of the apelin receptor APJ.
-
BioAge Labs, PTC Therapeutics, Biogen and others highlighted novel mechanisms targeting newer pathways in neurodegenerative diseases at the recent Discovery on Target meeting.
-
BioAge Labs to Present Data on Novel Brain-Penetrant NLRP3 Inhibitors for Treatment of Neurodegeneration and Brain Aging at Upcoming Conferences
10/13/2022
BioAge Labs, Inc. announced that it will present updates on its NLRP3 inhibitor program at two upcoming conferences in the United States, Neurodegeneration Targets and the Inflammasome Therapeutics Summit, and at the BIO-Europe 2022 conference in Leipzig, Germany.
-
BioAge Partners With Age Labs to Decipher Healthy Longevity Using Samples and Data From a Preeminent Northern European Biobank
8/24/2022
BioAge Labs, Inc., a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, announced that it has initiated a partnership agreement with Age Labs AS, a diagnostic company that develops tests for the early detection of age-related diseases.
-
BioAge CEO to Lead a Panel Discussion at the BIO 2022 Conference: “Targeting Aging Pathways to Treat Chronic Disease” — June 14, 2022, 11 AM
5/31/2022
BioAge Labs, Inc. announced that Kristen Fortney, PhD, CEO and Co-Founder of BioAge, will lead a panel discussion at the BIO International Conference held June 13–16, 2022 in San Diego, California.
-
BioAge Chief Business Officer Peng Leong Appointed Company’s First Head of Brain Aging
5/23/2022
BioAge Labs, Inc. announced that BioAge chief business officer Peng Leong, PhD, MBA, has been appointed as the Company’s Head of Brain Aging.
-
BioAge Developing a Novel Class of Potent NLRP3 Inhibitors With Distinct Structural and Pharmacologic Properties for Inflammatory and Age-Related Diseases
5/16/2022
BioAge Labs, Inc. announced that it is developing a family of novel small-molecule NLRP3 inhibitors as therapeutics for inflammatory and age-related diseases.
-
BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications
4/19/2022
BioAge Labs, Inc. announced that the first cohort has been dosed in a Phase 1b trial of BGE-105, a highly selective and potent small-molecule agonist of the apelin receptor APJ.
-
BioAge Labs presented new data demonstrating how its drug candidate BGE-175 is uniquely poised to tackle age-related immune system decline that leads to disease progression.
-
Nature Paper: BioAge’s Oral Drug Targeting the Aging Immune System Prevents Death From COVID-19 in Aged Mice
3/21/2022
BioAge Labs, Inc., a biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, announced that its clinical-stage oral drug BGE-175, which targets age-related immune deficiencies, protects aged mice from lethal infection with SARS-CoV-2, the virus that causes COVID-19.
-
BioAge appoints Dov Goldstein as Chief Financial Officer and Ann Neale as Chief Development Officer
11/17/2021
BioAge Labs, Inc. today announced the appointment of Dov Goldstein, M.D., M.B.A. as Chief Financial Officer (CFO) and Ann Neale as Chief Development Officer (CDO).
-
BioAge Appoints Rekha Hemrajani and Jason Coloma to its Board of Directors
8/19/2021
BioAge Labs, Inc. today announced the appointment of Rekha Hemrajani and Jason Coloma to the company’s board of directors.